Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations

Tazobactam/piperacillin (TAZ/PIPC), which is often combined with continuous renal replacement therapy (CRRT), induces renal excretion and is thought to have a high component removal rate for blood purification. CRRT procedures vary depending on the country, region, and institution. It is not clear w...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology: advances and applications 2017-01, Vol.9, p.39-44
Main Authors: Kohama, Hanako, Ide, Takeshi, Ikawa, Kazuro, Morikawa, Norifumi, Nishi, Shinichi
Format: Article
Language:English
Subjects:
Antibiotics
Antimicrobial agents
Chemotherapy
Continuous renal replacement therapy
dosage considerations
Drug dosages
Drug therapy
Hemodialysis
Intensive care
Kidneys
Original Research
Patients
Pharmacokinetics
Pneumonia
Renal replacement therapy
Sepsis
tazobactam/piperacillin
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tazobactam/piperacillin (TAZ/PIPC), which is often combined with continuous renal replacement therapy (CRRT), induces renal excretion and is thought to have a high component removal rate for blood purification. CRRT procedures vary depending on the country, region, and institution. It is not clear whether the dose of TAZ/PIPC for use in Japan can be determined based on studies conducted in other countries. Therefore, in this study, we examined the suitability of recommended dose in Japan. The study subjects consisted of 10 patients who received TAZ/PIPC during CRRT in the intensive care unit of Hyogo College of Medicine, Nishinomiya, Japan. We used a one-compartment model to characterize and parameterize the pharmacokinetics of TAZ/PIPC because their blood levels were eliminated monoexponentially. Compared with the data of healthy adults, the half-lives (t ) of both PIPC and TAZ were prolonged while their clearance rates decreased. For the continuous hemodiafiltration procedure adopted in Japan, we concluded that the dose and frequency were appropriate because the patients who received PIPC/TAZ 2.25 g twice a day during continuous hemodiafiltration maintained appropriate blood levels of both PIPC and TAZ.
ISSN:1179-1438
1179-1438
DOI:10.2147/CPAA.S127502